Press coverage about The Medicines (NASDAQ:MDCO) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. The Medicines earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.4256828514031 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Synlogic and Ginkgo Bioworks Announce Collaboration as First Step Toward Building an Unprecedented Discovery Engine for Novel Living Medicines in Neurological and Liver Disorders (markets.financialcontent.com)
- Facts, figures and statistics of: The Medicines Company, (NASDAQ: MDCO), PetMed Express, Inc., (NASDAQ: PETS … – Stocks In The News (press release) (tradingnewsnow.com)
- $20.38 Million in Sales Expected for The Medicines Company (MDCO) This Quarter (americanbankingnews.com)
- The Medicines Company (MDCO) stock’s Technical story – Wall Street Morning (wallstreetmorning.com)
- Stocks Alert: The Medicines Company, (NASDAQ: MDCO), Amdocs Limited, (NASDAQ: DOX), Lattice Semiconductor … – Stocks In The News (press release) (tradingnewsnow.com)
The Medicines (NASDAQ:MDCO) opened at $26.21 on Friday. The Medicines has a 52 week low of $25.40 and a 52 week high of $55.95. The company has a quick ratio of 1.79, a current ratio of 2.31 and a debt-to-equity ratio of 3.42.
A number of research firms have recently weighed in on MDCO. ValuEngine raised The Medicines from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Chardan Capital reissued a “buy” rating and set a $85.00 target price on shares of The Medicines in a report on Wednesday, September 20th. Guggenheim began coverage on The Medicines in a report on Monday, October 23rd. They set a “buy” rating and a $45.00 target price for the company. Citigroup raised The Medicines from a “sell” rating to an “outperform” rating in a report on Thursday, November 30th. Finally, Jefferies Group reissued a “buy” rating and set a $54.00 target price on shares of The Medicines in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $53.67.
In related news, Director Alexander J. Denner purchased 170,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average price of $30.03 per share, with a total value of $5,105,100.00. Following the completion of the purchase, the director now directly owns 6,663 shares in the company, valued at $200,089.89. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.22% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “The Medicines (MDCO) Earning Somewhat Positive Press Coverage, Analysis Finds” was first published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2017/12/10/the-medicines-mdco-earning-somewhat-positive-press-coverage-analysis-finds.html.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.